1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Zhejiang Xianju Pharmaceutical Co.,Ltd.

Zhejiang Xianju Pharmaceutical Co.,Ltd.

002332.SZ
Zhejiang Xianju Pharmaceutical Co.,Ltd.CN flagShenzhen Stock Exchange
8.29
CNY
-0.17
- -
8.20BMarket Cap
Zhejiang Xianju Pharmaceutical Co.,Ltd.
002332.SZ
(Shenzhen Stock Exchange)

Recent

price

8.29

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.94
2.2
2.57
3.06
3.2
3.1
2.74
3.18
3.97
4.07
4.38
4.41
4.43
4.17
4.03
3.76
3.77
Revenue per Share
0.16
0.17
0.16
0.08
0.07
0.13
0.16
0.23
0.33
0.45
0.55
0.63
0.76
0.57
0.4
0.45
0.37
Basic EPS, GAAP
0.12
-0.17
-0.34
-0.17
0.04
0.11
0.06
0.06
0.03
0.28
0.73
0.41
0.33
0.37
0.19
0.04
-0.25
Free Cash Flow per Basic Share
0.18
0.18
0.15
0.19
0.1
0.15
0.11
0.17
0.14
0.13
0.16
0.17
0.16
0.3
0.3
0.4
0.3
Dividend per Share
0.59
0.6
0.64
0.64
0.91
1.06
1
1.51
1.73
2.08
2.56
2.8
3.34
3.58
3.64
3.64
3.67
Book Value per Share
1.39
1.44
1.49
1.44
1.46
2.58
2.34
1.73
2.07
2.48
4.12
4.26
4.81
5.12
5.19
5.3
5.29
Tangible Book Value per Share
772
767
775
757
773
799
914
898
913
912
917
989
989
988
993
999
989
Basic Weighted Avg Shares
1,501
1,689
1,992
2,315
2,471
2,480
2,504
2,853
3,622
3,709
4,019
4,357
4,380
4,123
4,001
3,759
3,732
Sales/Revenue/Turnover
11.04
10.78
10.02
5.43
5.59
7.31
8.19
13.31
14.58
17.03
17.05
16.61
17.18
15.96
17.67
13.04
17.26
Operating Margin (%)
32
36
42
61
84
91
92
96
126
135
177
190
193
219
227
223
- -
Depreciation Expense
120
133
121
61
57
107
146
207
301
410
505
619
749
563
397
450
366
Net Income, GAAP
22.4
21.07
19.31
27.79
33.29
18.22
20.01
21.1
19.75
16.09
14.85
14.88
14.28
12.4
19.75
15.53
19.83
Effective Tax Rate (%)
8.01
7.87
6.05
2.62
2.29
4.3
5.84
7.24
8.32
11.07
12.55
14.21
17.11
13.66
9.93
11.96
9.8
Profit Margin (%)
683
431
156
61
59
864
761
1,085
1,115
1,109
2,125
2,186
2,465
2,353
2,486
2,254
2,241
Working Capital
65
65
78
190
134
84
- -
1,090
1,071
960
588
321
198
48
31
14
36
LT Debt
1,121
1,154
1,203
1,182
1,228
2,153
2,237
2,386
2,710
3,059
4,582
4,950
5,507
5,830
5,888
6,082
6,036
Total Equity
7.88
8.73
9.2
4.72
4.39
5.96
5.85
8.38
9.57
11.34
10.93
10.65
11.15
9.72
9.48
6.73
8.27
Return on Invested Capital (%)
15.02
16.36
14.4
8.88
7.2
10.29
11.92
9.15
9.22
11.87
13.97
17.43
20.65
15.11
10.56
11.84
9.84
Return on Capital (%)
26.45
28.93
25.17
12.38
9.59
13.79
16.6
18.22
20.53
23.57
23.76
24.18
24.65
16.45
11.1
12.39
10.15
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
28
28
346
LT Borrowings
20
23
24
LT Finance Leases
10
13
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
989
989
989
Market Capitalization
9,831
9,879
9,068

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
3,264
3,328
3,314
Cash, Cash Equivalents & STI
1,382
1,363
1,314
Accounts Receivable, Net
562
669
660
Inventories
931
922
957
Total Current Liabilities
778
717
1,073
Payables & Accruals
- -
- -
- -
ST Debt
28
28
346
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.63%
5.89%
3.29%
Free Cash Flow
86.48%
-35.14%
-79.9%
Net Income, GAAP
18.62%
0.53%
13.21%
Sales/Revenue/Turnover
4.67%
-1.19%
-6.04%
Total Cash Common Dividend
17.44%
27.8%
34.65%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,038
1,100
1,099
764
4,001
2025
1,008
861
933
- -
3,759
2026
918
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
- -
- -
- -
0.4
2025
0.15
- -
- -
- -
0.45
2026
0.09
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.3
2025
- -
- -
- -
- -
0.4
2026
- -
- -
- -
- -
- -
Similar Companies
Kyongbo Pharmaceutical Co., Ltd (214390.KS)
Tien Liang BioTech Co., Ltd. (4127.TWO)
Rapid Nutrition PLC (RPNRF)
Cannabis Suisse Corp. (CSUI)
Bakhu Holdings, Corp. (BKUH)
Aarti Pharmalabs Limited (AARTIPHARM.BO)
Business
Zhejiang Xianju Pharmaceutical Co., Ltd. manufactures and sells a comprehensive range of pharmaceutical products with a specialization in steroidal raw materials and formulations since its founding in 1972. The company's core products include steroids encompassing corticoids and sex hormones with over 100 varieties, along with key pharmaceutical formulations such as rocuronium bromide injection, finasteride tablets, misoprostol tablets, ropivacaine hydrochloride injections, flumazenil injections, prednisolone tablets, dexamethasone sodium phosphate injections, mifepristone tablets, progesterone injections, vecuronium bromide for injections, neostigmine methylsulfate injections, nicardipine hydrochloride injections, and various other steroid drugs and hormone formulations. The firm operates state-of-the-art manufacturing facilities that comply with cGMP, with certifications including FDA inspection and European Certificate of Suitability (CoS) for APIs. Zhejiang Xianju Pharmaceutical also provides a diverse product portfolio including tablets, capsules, injections, creams, gels, and powders. The company has established a strong domestic and international presence, exporting to over 30 countries including markets in Europe, North America, and Southeast Asia, with export revenue comprising around 40% of total sales. Recent major changes include participation in drug consistency evaluations for products such as Ethinylestradiol and Cyproterone Acetate Tablets and dexamethasone acetate tablets, reflecting the company’s commitment to regulatory compliance and product quality enhancement. Zhejiang Xianju Pharmaceutical engages in strategic partnerships, including investment adjustments with Quanxinjili Biotechnology to optimize its biological products segment. The company has increased investment in research and development, focusing on high-value generics and innovative drugs, allocating significant revenue portions to R&D to bolster its product pipeline and expand into therapeutic areas like oncology and cardiovascular treatments. This innovation-driven approach supports its stated mission to become one of the top suppliers of steroid medicines globally while fostering sustainable growth and expanding its international footprint and contract manufacturing services. Headquartered in Zhejiang, China, Zhejiang Xianju Pharmaceutical serves pharmaceutical wholesalers, hospitals, and international distributors. Its operational strategy includes robust supply chain management involving over 300 suppliers worldwide to maintain raw material quality and operational efficiency. The company’s ongoing initiatives emphasize sustainability, expanding product portfolios, and enhancing production capabilities to address evolving market demands in steroids and hormone pharmaceuticals. This detailed and evolving product and service offering positions Zhejiang Xianju Pharmaceutical Co., Ltd. as a leading and innovative entity in the steroid pharmaceutical manufacturing industry with a comprehensive global reach and a focus on compliance, quality, and pharmaceutical innovation.